RARE

Ultragenyx Pharmaceutical Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Did you know?

Capital expenditures decreased by 14% from FY24 to FY25.

Current Price

$24.77

+0.32%

GoodMoat Value

$28.14

13.6% undervalued

Profile

Valuation (TTM)

Market Cap$2.39B

P/E-4.16

EV—

P/B—

Shares Out96.48M

P/Sales3.55

Revenue$673.00M

EV/EBITDA—

Ultragenyx Pharmaceutical Inc (RARE) Valuation

RARE Fair Value Estimate

$28.1413.6% undervalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

RARE Valuation Metrics

FCF$-472.00M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

RARE Valuation & Fair Value Analysis

Ultragenyx Pharmaceutical Inc (RARE) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Ultragenyx Pharmaceutical Inc is $28.14. The current stock price is $24.77, suggesting the stock is 13.6% undervalued.

The price-to-earnings (P/E) ratio is -4.16. Price-to-sales ratio is 3.55. PEG ratio is 0.57.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Ultragenyx Pharmaceutical Inc's intrinsic value.